CCMW
ZYNE

Cypress Capital Management (Wyoming)’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100
Closed -$1K – 338
2017
Q3 		$1K Hold
100
– – ﹤0.01% 263
2017
Q2 		$1.7K Buy
+100
New +$1.99K ﹤0.01% 254

Other funds holding ZYNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s ZYNE Position: Q4 2017 in Review

Cypress Capital Management (Wyoming) sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2017, closing a stake of 100 shares — an estimated $1K sold.

Cypress Capital Management (Wyoming) first reported a position in ZYNE in Q2 2017 and held it in 2 quarters. The position peaked at $1.7K in Q2 2017. 64 funds tracked by Wall St. Rank hold ZYNE as of Q4 2017.

  • Cypress Capital Management (Wyoming) reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2017 after selling out during the quarter.
  • Cypress Capital Management (Wyoming) sold 100 Zynerba Pharmaceuticals, Inc shares in Q4 2017, an estimated $1K.
  • Cypress Capital Management (Wyoming) first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and held it in 2 quarters.
  • Cypress Capital Management (Wyoming)'s Zynerba Pharmaceuticals, Inc position peaked at $1.7K in Q2 2017.
  • 64 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2017.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q4 2017, filed 31 Jan 2018.